{"url_path":"/sec/telo/8-k/2026-05-20/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1971532/0001493152-26-024517-index.html","accession_number":"0001493152-26-024517","cik":"0001971532","ticker":"TELO","issuer_name":"Telomir Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1971532/0001493152-26-024517-index.html","primary_entity_key":"0001971532","primary_entity_name":"Telomir Pharmaceuticals, Inc."},"word_count":186,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure**\n\n** **\n\nOn\nMay 20, 2026, Telomir Pharmaceuticals, Inc. issued a press release announcing publication of a peer-reviewed\npreclinical study titled *“Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient\nzebrafish model of Wilson’s disease”* in the journal *Advances in Redox Research*.\n\n \n\nThe\npublication reported preclinical findings evaluating Telomir-1 (Telomir-Zn) in cellular systems and a zebrafish model of Wilson’s\ndisease, including findings demonstrating reductions in oxidative stress signaling, intracellular calcium dysregulation, hepatic copper\naccumulation, liver injury biomarkers, histopathological degeneration, and improvements in locomotor performance and survival outcomes.\n\n \n\nIn accordance with General\nInstruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any\nregistration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange\nAct, except as shall be expressly set forth by specific reference in such a filing."}